InterCure Ltd. (INCR) shareholders back proposal at August 11, 2026 special meeting

Rhea-AI Filing Summary

InterCure Ltd. reports that an Extraordinary General Meeting of Shareholders held on August 11, 2026 approved the proposal presented to shareholders, with the required majority. The proposal is described in the Notice and Proxy Statement dated July 22, 2026, which had been furnished earlier to the U.S. Securities and Exchange Commission, including an amendment dated July 27, 2026.

Key Terms

Extraordinary General Meeting of Shareholders, Report of Foreign Private Issuer, Proxy Statement

3 terms

Extraordinary General Meeting of Shareholders regulatory

"On August 11, 2026, an Extraordinary General Meeting of Shareholders"

A meeting called by a company outside its regular annual meeting to address urgent or special matters that cannot wait until the next scheduled meeting. Investors attend or vote to decide on actions such as major deals, leadership changes, capital-raising, or rule changes; think of it as an emergency board meeting where shareholders have a direct say and the outcomes can quickly change a company’s strategy, ownership stakes, or financial prospects.

Report of Foreign Private Issuer regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

Proxy Statement regulatory

"The proposal was described in the Company’s Notice and Proxy Statement"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

FAQ

What did InterCure Ltd. (INCR) announce in its August 2026 Form 6-K?

InterCure Ltd. reported that shareholders at an Extraordinary General Meeting on August 11, 2026 approved a proposal. The approved proposal was previously described in the company’s July 22, 2026 Notice and Proxy Statement filed with the SEC.

When was the Extraordinary General Meeting of InterCure Ltd. (INCR) held?

The Extraordinary General Meeting of InterCure Ltd. shareholders was held on August 11, 2026. At this meeting, shareholders approved the proposal brought before them, in line with the required majority for that proposal.

Was the proposal at InterCure Ltd.’s (INCR) Extraordinary General Meeting approved?

Yes, the proposal presented at InterCure Ltd.’s Extraordinary General Meeting was approved in accordance with the required majority. Details of the proposal are contained in the company’s July 22, 2026 Notice and Proxy Statement.

Where can investors find details of the proposal approved by InterCure Ltd. (INCR)?

Details of the approved proposal are in InterCure Ltd.’s Notice and Proxy Statement dated July 22, 2026. That document was furnished to the SEC on Form 6-K, and later amended on July 27, 2026.

Which executive signed InterCure Ltd.’s (INCR) August 2026 Form 6-K?

The report was signed by Amos Cohen, Chief Financial Officer of InterCure Ltd.. His signature confirms the company’s authorization of the disclosure regarding the Extraordinary General Meeting and its outcome.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/11/2026 - 09:28 AM Accepted by SEC EDGAR 08/11/2026 - 09:28 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2026 (Report No. 2)

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On August 11, 2026, an Extraordinary General Meeting of Shareholders (the “Meeting”) of InterCure Ltd. (the “Company”) approved the proposal brought before the Company’s shareholders at the Meeting, in accordance with the majority required for such proposal. The proposal was described in the Company’s Notice and Proxy Statement with respect to the Meeting, dated July 22, 2026, attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 22, 2026, as amended on July 27, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INTERCURE LTD.
Date: August 11, 2026	/s/ Amos Cohen
	Amos Cohen
	Chief Financial Officer